A study of combination of Farnesoid X receptor (FXR) agonists and cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH)

Trial Profile

A study of combination of Farnesoid X receptor (FXR) agonists and cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH)

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Cenicriviroc (Primary) ; Farnesoid X-activated receptor agonists (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top